Across TCGA pan-cancer cohorts, RNASE7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RNASE7 data layer compared with 22 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RNASE7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RNASE7 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.
LSCC and HNSC are the cancer types where RNASE7 mass-spec protein most reproducibly stratifies survival.